⌕
Ascendis Pharma · ASND · Nasdaq
Tenet 53 · Mixed
Compare
$271.19−0.20%At closeTenet 53 · Mixed
$271.19−0.54 (−0.20%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ascendis Pharma (ASND) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~213.0%/yr (FY21→FY25), net margin −31.7%. Worth your attention in FY25: Share count (+8.9%) and Capex step-up ($10.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲124.5%
845.1
FY21→FY25CAGR +213.0%/yr
Net income ($M)▲31.6%
−267.6
FY21→FY25CAGR —
Free cash flow ($M)—
53.3
no value for 2 of 5 yearsCAGR —
Diluted EPS▲34.7%
−4.41
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+8.9%

56.9mn → 62.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$10.0M

▲574% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
38%

$20.4M returned vs $53.3M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)845.1Revenue−111.4COGS733.8Gross profit−356.3R&D−537.4SG&A−159.9Op income−107.7Tax & other−267.6Net income

-32¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 54.7% → 86.8%. Net margin -31.7% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
845,146.9845,146.9376,404.8295,043.554,745.98,803.1▲124.5%+213.0%
Cost of revenue
111,392.2111,392.245,811.549,109.712,984.23,987.3▲143.2%+129.9%
Gross profit
733,754.7733,754.7330,593.3245,933.741,761.84,815.8▲122.0%+251.3%
Research & development
356,329.6356,329.6317,779.8457,362.8406,121.8334,862.3▲12.1%+1.6%
Selling, general & admin
537,352.7537,352.7301,361.1292,490.3236,668.6181,291.7▲78.3%+31.2%
Total operating expenses
893,682.3893,682.3619,140.9749,853.2642,790.4516,154.0▲44.3%+14.7%
Operating incomefeeds ROC rank
−159,927.6−159,927.6−288,547.6−503,919.5−601,028.6−511,338.2▲44.6%—
Other income, net
−89,639.6−89,639.6−97,794.2−20,578.6−17,120.076,790.4——
Pretax income
−249,567.2−249,567.2−386,341.8−524,498.1−618,148.6−434,547.8▲35.4%—
Income tax
18,053.518,053.55,013.08,078.65,752.3−415.4▲260.1%+46.4% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−267,620.7−267,620.7−391,354.7−532,576.7−623,900.9−434,132.4▲31.6%—
Per share
Diluted EPSbuyback-sensitive
−4.41−4.41−6.76−9.46−11.13−7.00▲34.7%—
Diluted shares (mn)
61.9861.9860.6957.7157.1556.94▲2.1%+2.1%
Margins
Gross margin81st pct in Healthcare
86.8%86.8%87.8%83.4%76.3%54.7%▼1.0pp+32.1pp
Operating margin
−18.9%−18.9%−76.7%−170.8%−1097.9%−5808.6%▲57.7pp+5789.7pp
Net margin19th pct in Healthcare
−31.7%−31.7%−104.0%−180.5%−1139.6%−4931.6%▲72.3pp+4899.9pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-11 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Ascendis Pharma's revenue last fiscal year?

Ascendis Pharma reported revenue of $845.1M in fiscal 2025, up 124.5% from fiscal 2024.

What was Ascendis Pharma's net income?

Ascendis Pharma reported net income of −$267.6M in fiscal 2025, a net margin of −31.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.